Company profile

HALOZYME THERAPEUTICS, INC.

NASDAQ:HALOBiotechnology: Biological Products (No Diagnostic Substances)

Drug pipeline (2)

Asset	Stage	Revenue	Trials	Status
HYLENEX RECOMBINANT	approved	—	10	approved
PEGVORHYALURONIDASE ALFA	phase2	—	6	completed, terminated

Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.

Clinical trials (32)

NCT ID	Phase	Status	Start	Completion	Sponsor name	Title
NCT00979875	phase1	completed	2009-09-01	2010-02-01	Halozyme Therapeutics	A Pharmacokinetic and Glucodynamic Study of Subcutaneously Administered Insulin Analogs With rHuPH20 Compared to Insulin Analogs Alone
NCT02346370	phase1	terminated	2015-02-10	2016-08-09	Halozyme Therapeutics	A Phase 1b Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Docetaxel in Subjects With Recurrent Previously Treated Locally Advanced or Metastatic NSCLC
NCT00311519	phase4	completed	2005-11-01	—	Halozyme Therapeutics	A Phase IIIB Dose Comparison Study of Subcutaneous Hydration With and Without Human Recombinant Hyaluronidase (HYLENEX) in Volunteer Subjects
NCT03662334	phase4	completed	2013-10-03	2014-02-27	Halozyme Therapeutics	A Study of Continuous Subcutaneous Insulin Infusion (CSII) Pump Function in Subjects With Type 1 Diabetes With Recombinant Human Hyaluronidase (rHuPH20)
NCT02563548	phase1	completed	2015-10-22	2019-03-26	Halozyme Therapeutics	A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selected Hyaluronan High Solid Tumors

FDA applications (2)

Application

Approved

Type

Applicant

Products

BLA 021859

2005-12-02

BLA

HALOZYME THERAPEUTICS, INC.

BLA 761313

—

BLA

HALOZYME THERAP